chronic cough
Conditions
Interventions
Experimental group:Conducting Bronchial Provocation Test with Methacholine Chloride
Sponsors
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily sign the informed consent form; 2. Male or female, aged 18-65 years (including 18 and 65 years old); 3. Having cough as the main symptom, with chronic cough lasting more than 8 weeks; 4. Normal lung function tests (FEV1 >= 80% of the predicted value); 5. No obvious lesions observed on chest X-ray or chest CT (valid within 2 months), chest imaging does not show abnormalities that researchers consider could cause chronic cough; 6. Body Mass Index (BMI) = weight (kg) / height^2 (m^2), within the range of 18.5–27.0 (including boundary values).
Exclusion criteria
Exclusion criteria: 1. Those who have a history of allergy to this type of reagent; Have a definite hypersensitivity to inhaled provocants; 2. Patients with clinically confirmed cough variant asthma; 3. Those who have undergone intracranial, ophthalmic, otolaryngological diseases, respiratory diseases, thoracic or abdominal surgery within 6 months before the trial; 4. Those who have had a fatal asthma attack, or have had an asthma attack in the past 3 months that required mechanical ventilation treatment; 5. Respiratory tract infection and hemoptysis in the past four weeks; 6. Previous severe circulatory system diseases, hepatobiliary system diseases, digestive system diseases, urinary system diseases, kidney diseases, blood diseases, endocrine system diseases, immune system diseases, malignant tumors, etc.; Those with respiratory diseases such as concurrent pneumothorax or infectious diseases such as active tuberculosis; 7. Patients with diseases that may have an impact on the use of cholinergic drugs (epilepsy, bradycardia, coronary artery occlusion, vagus nerve tension, thyroid disease, arrhythmia, peptic ulcer, urinary tract disorders, treatment of myasthenia gravis, etc.); 8. Patients with a history of drug dependence or alcohol dependence; 9. Pregnant and lactating women; 10. Subjects with dyspnea, wheezing, and wheezing on the day of the test; 11. Poor cooperation in basic lung function tests and failure to meet quality control requirements; 12. Drugs that affect airway systolic function and airway inflammation, thereby affecting airway reactivity before the test and cannot be stopped (bronchodilators, glucocorticoids, antiallergic drugs, triene receptor antagonists, etc.); 13. Have participated in clinical studies of other projects within 3 months before signing the informed consent form; 14. Subjects who are not suitable for inclusion in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse Event;Peak Expiratory Flow; Forced Expiratory Volume in 1 Second;Forced Vital Capacity; | — |
Countries
China
Contacts
Public ContactQu Jieming
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Outcome results
None listed